Welcome to Galenicum! APRIL, 2013

Similar documents
REGULATORY AFFAIRS UNIVERSITY JOINS INDUSTRY - BARCELONA MARCH 15 TH, 2017 GALENICUM REGULAOTRY AFFAIRS 1

Partner with the Global Leader in Drug Delivery Systems

Taking Health & Nutrition to the NEXT Level

A GLOBAL LEADER IN PERSONALIZED NUTRITION

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

Health for Humanity 2020 Goals 2

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

EU5 Bariatric Surgery Procedures Outlook to 2020

概美科技. GuideMia Technologies, LLC Sept

Managing Global EHS Risk: A Solution. Katie Florio Alizabeth Aramowicz Smith July 19 th, 2017

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances

Mexico Ostomy Drainage Bags Market Outlook to 2020

Asia-Pacific Electrophysiology Market Outlook to 2020

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

The Cigarette Market in Greece

For personal use only

A world leader in allergy immunotherapy

Location of HENGRUI. The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

040716_ANDI_VENTIS WEBSITE(new) Printout 1. HOME PAGE. Welcome to our world of Dry Powder Inhalers!

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

The Cigarette Market in Saudi Arabia

Allergy Therapeutics. Corporate Presentation. Proactive Investors 28th January 2016 Ian Postlethwaite, Finance Director

The Cigarette Market in Netherlands

Leader in custom manufacturing. for the pharmaceutical and nutraceutical industries.

Harm de Wildt MD TNI

DS-8201 Strategic Collaboration

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008

Value growth in Human Nutrition & Health

Forward-Looking Statements

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Health and nutrition, at the core

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

For personal use only. Investor Briefing. Bayswater, 1 st December 2016

The Dental Corporation Opportunity

BRIEF INTRODUCTION MEHECOS 1

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries.

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Business Proposal Summary

UN Panel Discussion Millennium Development Goals. Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010

67 Years of Leadership in Pharmacy. A Journey of Continuous Improvement

Generic HCV DAAs. Economics and sustainability. Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Our proposal relies in the development and implementation of effective technology innovations in the world of Omega 3 fatty acids.

School of Management, NEW JERSEY INSTITUTE OF TECHNOLOGY Master of Science in Management (MSM)

Because you care about CONSUMERS HEALTH

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

Tobacco Insights May

Swedencare. Presentation CEO Håkan Lagerberg CFO Jenny Graflind

The Cigarette Market in Belarus

Partnering for Growth

Nestlé Investor Seminar 2008

Investor Presentation

Environmental, Health and Safety

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

WHAT DO MANUFACTURERS AND IMPORTERS HAVE TO DO TO PREPARE FOR EU MEMBERSHIP?

Partner with the Global Leader in Drug Delivery Systems.

Tamsulosin Hydrochloride 0.4 mg Capsule

Partner with the Global Leader in Drug Delivery Systems.

Global Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast ( )

Investor Presentation June 2012 NASDAQ: CEMI

NOW easily fits that description today as a top-selling brand in health food

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics

The Nutraceutical Solutions! CERTIFIED ISO

Establishing human vaccine manufacturing in Southern Africa

Investor Presentation September Cogstate Ltd. All rights reserved.

EXHIBITOR INVITATION. Join us in Chengdu to be part of the dental health business event in West China region

TOEIC BLANC INCOMPLETE SENTENCES CORRECTION PARTIE 5

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Gavi s private sector engagement approach

DARA Reports Year-End 2012 Financial Results

CELLMID LIMITED EGM PRESENTATION

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

View Report Details. Global Coronary Stent Market

2007 FIP World Congress of Pharmacy and Pharmaceutical Sciences September 3, 2007 Beijing, China

Graft Delivery Devices

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

2. Develop teams of four students (there are seven unique roles in ABIG Company).

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Improving access to medicines for patients in lower-income countries

Speed & scale to added sugars reduction: The ambition of the European soft drinks industry

Consumer Health Care V5.0_2013

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing

ARE Position Paper: Women and Sustainable Energy

Investment in MGC Pharmaceuticals

Hilleman Laboratories

FITNESS EQUIPMENT & GYM DESIGN

GAVI, THE VACCINE ALLIANCE

Transcription:

Welcome to Galenicum! APRIL, 2013

Our corporate image comes from the sunrise. Night represents disease, daylight means health and the sunrise stands for overcoming GALENICUM CORPORATE PRESENTATION 3

Who we are Our expertise Ten year strategic plan Working in International GALENICUM CORPORATE PRESENTATION 4

Who we are - Introduction to Founders Joaquim Domingo - CSSO Erich Büchen - COO Alejandro Ollé - CFO 39 years old MSC in Engineering by UPC Previous experience in management consulting 40 years old MSC in Economics by ESADE Previous experience in chemical trading 39 years old MSC Engineering by UPC Previous experience in management consulting GALENICUM CORPORATE PRESENTATION 5

Who we are - Facts We are a young innovative oriented company Income: 84 Mn in 2014 Winner of the European Business Awards 2014 Offices in Perú, Chile, Brazil, China, Malta and Barcelona We deliver excellence through different business models both, in the B2B and B2C business GALENICUM CORPORATE PRESENTATION 6

Who we are - Our history Galenicum foundation in January 2003 Appointed as Dr. Reddy s Agent for Spain Advisory entry strategy project for a generic multinational in Spain 1 st patent for API filed Launch of: Rivastigmin Sildenafil Atorvastatin LAB expansion project Establishment t of Brazil and Peru Offices Relaunch of Sildenafil Kick-off SAG manufacturing 1 st formulation license sold 1 st development started 1 st MA for generic product in Spain 1 st contract manufacturing project started Launch Olanzapine Establishment t of Kuwait Partnership Launch of Dexketoprofen Launch of Citicoline sticks, Almotriptan and creams 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2014 Galenicum China Office December 2004 Galenicum Madrid Office Galenicum India Office Galenicum Malta office New Barcelona Office Galenicum Brazilian Office Galenicum Office in Chile Launch of 1st product in Peru: Anastrozole Acquisition of SAG manufacturing Madrid Regulatory Affairs Department started Galenicum Control Lab commissioned & GMP approved Galenicum Office in Peru GALENICUM CORPORATE PRESENTATION 7

GALENICUM CORPORATE PRESENTATION 8

Who we are - Figures Revenues Headcount development K Eur Growth of own products Launch of Dexketoprofen 73.000 Launch of Citicoline, Almotriptan and Creams 84.000 61.200 66.000 Headcount # 201 Launch of: - Sildenafil - Atorva - Rivastigmine 43.200 3 8 9 10 15 18 28 28 63 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Start of first FP projects 12.000 7.400 7.950 2.400 3.350 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 (Forecast) 100% of the Galenicum team holds a university degree - Pharmacy: 28% - Engineering: 13% - Business: 19% - Chemistry: 17% - PhD: 9% - Others: 14% We achieve consistent growth by investing in our people and in R&D GALENICUM CORPORATE PRESENTATION 9

Who we are Our expertise Ten year strategic plan Real Experiences and Recruiting GALENICUM CORPORATE PRESENTATION 10

20 Patents Applications Completed 2014 25 Patents Applications Completed 2015 GALENICUM CORPORATE PRESENTATION 11

GALENICUM CORPORATE PRESENTATION 12

GALENICUM CORPORATE PRESENTATION 13

Affordability Best price-quality relation Safety and eficiency Bioequivalent Products Quality Made in Europa GALENICUM CORPORATE PRESENTATION 14

Our expertise Galenicum s business model integration 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2014 Phase I Sale of API's Phase II Sale of FDF of Principals Development and Sales of Own Products Phase III Own brand FDFs Phase IV Manufacturing GALENICUM CORPORATE PRESENTATION 15

Our expertise - Two business models API s Sourcing of APIs for R&D and industrial products B2B Finished products Licensing of CTD dossiers and supply - Own Products - Products from principals: e.g. Apotex,Cinfa, Cipla Quality control Batch release services - GMP approved laboratory Expertise Manufacturing Own manufacturing (SAG manufacturing) B2C Finished products Commercialization of own products directly to hospitals and pharmacies in LATAM Own branding Own branding strategy for the B2C business model GALENICUM CORPORATE PRESENTATION 16

Who we are - Main Customers Customers GALENICUM CORPORATE PRESENTATION 17

Who we are Our expertise Ten year strategic plan Working in International GALENICUM CORPORATE PRESENTATION 18

Ten year strategic plan - Manufacturing facility Total area: 74.000 m² Warehouse: 5.317 m 2 Quality Labs: 647 m 2 Buildings: 24.250 m² Central Weight Area: 230 m2 Manufacturing: 2.569 m 2 Packaging: 3.712 m 2 Admin. Offices 1.125 m 2 General Areas: 534 m 2 Internal Expansion Area : 1.154 m 2 Land built: 17.740 m² Expansion areas Land to be built 24.000 m² - Indoor: 1.154 m² - Outdoor: Buildings 50.000 m² GALENICUM CORPORATE PRESENTATION 26

Ten year strategic plan - Manufacturing facility Capacidad Productiva de SAG Capacities 3 Shifts 2014 2015 Solids Compression 2.300 MM Tablets 2.300 MM Tablets Coating 480 MM Coated Tablets 2.700 MM Coated tablets Blister 125 MM Blisters 170 MM Blisters Blister Packs 31 MM Blister Packs 42 MM Blister Packs Creams kg 420.000 kg 420.000 kg Tubes 43 MM Tubes 43 MM Tubes Liquids Litres 1,5 MM Litres 1,5 MM Litres Bottles 18 MM Bottles 18 MM Bottles Sticks 17,5 MM Sticks 17,5 MM Sticks Sticks Packs 1,3 MM Stick Packs 1,3 MM Stick Packs *En máxima capacidad podría satisfacer el 30% de la demanda total de Perú SAG MANUFACTURING can supply the 30% of Peru s total market GALENICUM CORPORATE PRESENTATION 27

Who we are Our expertise Ten year strategic plan Working in International GALENICUM CORPORATE PRESENTATION 28

Working in International GENERAL MANAGEMENT Definition of the Development strategy International Department SUBSIDIARIES DISTRIBUTORS + - Front Office SALES MKTG HR FINANCE SUPPLY CHAIN REGULATORY Back Office GALENICUM CORPORATE PRESENTATION 29

Working in International Academic Background Bachelor in Business Administration, Economics, Engineering, Pharmacy Master in Business Previous experience in Consulting or FMCG Excellent level of foreign languages Soft skills Entrepreneurial spirit Business oriented Enjoys challenges and strategic thinking Persuasive and encouraging Strong organizational and time management skills Leadership GALENICUM CORPORATE PRESENTATION 30

Working in International Tasks in International business development Sales strategy definition Marketing campaigns design and implementation Pricing strategy Budget planning and approval Set up of new and longstanding relationships with partners Pipeline evaluation and tracking Identification of new business opportunities Coordination and alignment of all the different subsidiaries GALENICUM CORPORATE PRESENTATION 31

GALENICUM CORPORATE PRESENTATION 32

Welcome to Galenicum! APRIL, 2013